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Abstract
Background: There is debate concerning methods for calculating numbers needed to treat
(NNT) from results of systematic reviews.
Methods: We investigate the susceptibility to bias for alternative methods for calculating NNTs
through illustrative examples and mathematical theory.
Results: Two competing methods have been recommended: one method involves calculating the
NNT from meta-analytical estimates, the other by treating the data as if it all arose from a single
trial. The 'treat-as-one-trial' method was found to be susceptible to bias when there were
imbalances between groups within one or more trials in the meta-analysis (Simpson's paradox).
Calculation of NNTs from meta-analytical estimates is not prone to the same bias. The method of
calculating the NNT from a meta-analysis depends on the treatment effect used. When relative
measures of treatment effect are used the estimates of NNTs can be tailored to the level of
baseline risk.
Conclusions: The treat-as-one-trial method of calculating numbers needed to treat should not be
used as it is prone to bias. Analysts should always report the method they use to compute estimates
to enable readers to judge whether it is appropriate.
Introduction
Cates [1] considers "how should we pool data?", focusing
in particular on the calculation of the number needed to
treat (NNT). He explains how Simpson's paradox may
lead to the wrong answer when the NNT is calculated in a
particular way. Moore and colleagues [2], responding to
Cates, focus on the specific example used by Cates and ad-
dress the question "which data should be pooled?". Un-
fortunately, they largely ignore Cates' methodological
point. We suspect that many readers of these two articles
will come away rather confused, so our aim is to try to
clarify some of these issues.
First, we note that incorrect methods may give the right
answer some or even most of the time, but that does not
mean that they should be used or recommended. They
might be copied by others and used in situations where
they do not work. For example, in the fraction 16/64 we
can cancel the two sixes to give the right answer of 1/4. This
method will almost always give the wrong answer, howev-
er, such as in the fraction 26/61.
Methods of meta-analysis
Combining results of several studies
Meta-analysis is a statistical method for combining the re-
sults from two or more independent studies. It is used
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when it is felt that the studies are similar enough to make
combining the results a sensible thing to do. Judging com-
binability requires what Moore et al refer to as clinical
common sense, although there are additional considera-
tions such as the quality of the separate studies.
Meta-analysis is a two-stage process. First the data for each
study are summarised, and then those summaries are sta-
tistically combined. All widely used methods of meta-
analysis are of this type [3]. The method used (and recom-
mended) by Moore and colleagues for calculating the
number needed to treat uses the data as if they came from
a single study, and is not a valid approach to meta-analy-
sis; indeed it is not really a meta-analysis. They argue that
it generally gives similar answers to those obtained using
the correct approach. This is true, but sometimes it gives
the wrong answer, as Cates shows and we will also show.
One complication is that both of these articles refer to
'pooling', a term that does not have a unique meaning.
Cates [1] uses it to mean combining the treatment effects
from separate studies while Moore et al [2] use the term to
mean adding up the numbers as if the data were all from
one large study. We will refer to two stage meta-analysis
(as recommended by Cates) as standard meta-analysis,
and adding up the numbers (as recommended by Moore
et al) as the 'treat-as-one-trial' method.
Calculating the number needed to treat (NNT)
For a single trial with a binary outcome the number need-
ed to treat (NNT) is estimated as the reciprocal of the ab-
solute risk difference. In meta-analysis the situation is
complicated by the fact that there are several possible
ways of summarising effect – risk ratio, odds ratio, and
risk difference (and there are in fact two risk ratios) [4,5].
The principles of meta-analysis and the arguments below
apply regardless of the choice of outcome summary.
The NNT can be obtained directly from a meta-analysis
that pools risk differences from several trials. However, it
is common for systematic reviews to include trials with
different baseline risks (estimated by the event rate in the
control group) due to differences in trial characteristics
such as case-mix and duration of follow-up. Inclusion of
trials with different baseline risks is not always a problem.
This is because the treatment effect may be quite constant
across trials, if expressed as relative effects (such as the
odds ratio or relative risk), rather than as absolute effects
(such as the risk difference)[4–6]. As Cates notes, the NNT
can be estimated from an analysis based on relative effect
measures, if one specifies the anticipated (baseline) risk in
untreated patients. Further, this allows the NNT to be tai-
lored to patients with differing baseline risks, rather than
quoting one overall NNT [7,8].
Moore et al calculate a single NNT from several trials di-
rectly from the proportions, with events summed over all
studies.
Impact of unbalanced numbers
The vast majority of RCTs have approximately equal num-
bers in each arm. Unequal numbers may occasionally
arise from deliberate unbalanced randomisation but
more often because two or more groups receiving similar
treatments are combined for a meta-analysis.
Imbalance in one or more trials has no effect on standard
meta-analysis. Separate estimates are obtained from each
trial that take correct account of the numbers per arm. No
trial influences the impact of the other trials. By contrast,
the treat-as-one-trial approach, which adds all the data for
like arms across trials, certainly can be influenced by im-
balance. As Cates notes, this is a form of Simpson's para-
dox (which is not a true paradox but rather a bias).
Consider, for example, two RCTs from the systematic re-
view of nicotine gum [9] referred to by Cates. These trials,
both with unbalanced allocation, are summarised as fol-
lows:
Both trials showed a risk difference of 0.06 (or 6%). Com-
mon sense (statistical rather than clinical) tells us that
when we pool the results of these two trials we should get
an answer that lies between those of the two trials being
combined. Results of meta-analyses of these two trials are
shown in Table 1(a). While the standard approach indeed
gives a pooled risk difference of 6%, the treat-as-one-trial
method pools two trials each with a risk difference of 6%
and gets an estimated effect of 3%. Consequently the NNT
from this approach is 31 compared to the correct value of
17. This simple example shows why Moore et al are wrong
to dismiss Simpson's paradox (and Cates' argument).
The full review [10] includes 51 trials of which several are
unbalanced. Overall, summing across the 51 trials the
quit rates in the intervention and control groups were
1508/7674 (19.7%) and 1110/9613 (11.5%) respective-
ly. Meta-analyses of the 51 trials using the two methods
just discussed are shown in Table 1(b). Even here, where
most trials are balanced, the treat-as-one-trial approach
gives an incorrect answer. In fact, the 95% confidence in-
tervals for the two estimates barely overlap. Thus the state-
ment of Moore et al that "the problem of trial imbalanceBMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/3
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comes from combining different interventions as if they
were a single intervention" is incorrect. We also note that,
compared to standard meta-analysis, the treat-as-one-trial
method gives greater weight to large trials and will tend to
give narrower confidence intervals.
The risk of such imbalance having an effect increases with
(a) increasing discrepancy in size of treatment groups, (b)
increasing variation in control group event rates, (c) in-
creasing heterogeneity in treatment effects between the
studies. Standard (stratified) meta-analytical methods are
not affected by imbalance and so are not affected by Simp-
son's paradox.
Discussion
Cates' illustrative example
Cates used for illustration a subset of the trials included in
a systematic review published on the Cochrane Library
[10]. He used the ten trials of high intensity nursing inter-
ventions to encourage smoking cessation – his paper
shows the actual results of each trial. He demonstrates
that the treat-as-one-trial approach gives an answer in the
opposite direction to that from standard meta-analysis,
and attributes this to the fact that the analysis is not im-
mune to the effect of Simpson's paradox. Moore and col-
leagues believe that these trials should not all be grouped
together and that the paradoxical answer arose from the
inappropriate pooling. They thus split the trials by setting
– seven trials done in hospital settings and three in prima-
ry care. We agree that it may be wise to investigate whether
setting affects effectiveness before combining all of these
trials, but we do not agree with the method by which
Moore et al undertakes this investigation, nor their impli-
cation that the methodological problem could only occur
if one pools trials inappropriately.
Moore et al show that the results are somewhat different
in the two subgroups (their table 1). They argue that
among hospital patients the relative treatment benefit was
statistically significant (RR = 1.3, 95% CI 1.1 to 1.6) and
that the NNT of 14 (95% CI 9 to 26) is a useful result. In
unselected primary care patients (their definition) there
was a not a statistically significant result and the NNT was
222. They conclude that nursing interventions are "prob-
ably ineffective" in these patients. Our comments are:
1 The evidence of an effect in hospital patients is fairly
weak, being only marginally statistically significant.
2 The estimated effect in primary care has a confidence in-
terval that goes way above the whole CI for secondary
care, so that it is quite inappropriate to dismiss the inter-
vention on such slight evidence. (However, it seems as if
the result for this group is based on a random effects anal-
ysis.)
3 The comparison of the subgroups should not be based
on comparison of P values (one significant and one not),
whether explicit or, as here, implicit [11]. By a formal test
of interaction the pooled results from the two groups of
trials are not significantly different.
4 No account is taken of the quality of these trials. For ex-
ample, two trials (including the largest) were not properly
randomised and another was a cluster randomised trial
that was analysed wrongly [10].
5 Interested readers should consult the Cochrane review
[10] to get the 'real' results. The review includes data from
additional trials and analyses stratified by patient type
and type of intervention. The authors conclude that the
intervention is beneficial in both hospitalised and non-
hospitalised patients (RR = 1.28 (1.03 to 1.61) (random
effects model)), there being no-significant difference in
RR between primary care and secondary care patients (P =
0.42). Applying the overall relative increase in cessation
rates of 28% gives: (a) an NNT of 89 for primary care tri-
als, based on the median placebo quit rate of 4%; (b) an
NNT of 12 for secondary care trials, based on the median
placebo quit rate of 30%.
Table 1: Results of meta-analyses of trials of nicotine gum to reduce smoking using standard and 'treat-as-one-trial' methods, with risk 
difference as effect measure
Pooled risk difference (95% CI) P NNT
(a) Two selected trials (see text)
Standard meta-analysis (Mantel-Haenszel method) 0.060 (0.025 to 0.095) 0.001 16.7
Treat-as-one-trial 0.033 (0.001 to 0.064) 0.04 30.7
(b) All 51 trials
Standard meta-analysis (Mantel-Haenszel method) 0.061 (0.050 to 0.071) <0.001 16.4
Treat-as-one-trial 0.081 (0.070 to 0.092) <0.001 12.3BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/3
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In addition, one of the trials that Moore et al included as
a trial of "unselected primary care patients", was in fact
done in patients with cardiovascular problems [12]. Our
common sense tells us to exclude that trial. We summarise
the results of meta-analyses in Table 32, here using the
risk ratio (relative risk) as Moore et al did. (We cannot ex-
actly reproduce the results given by Moore et al as we are
not sure which method they used to obtain the relative
risks.)
We agree with Moore et al that it helps to split the trials by
setting to gauge the differential impact of the intervention
– the NNTs in the two settings are clearly different. But no-
tably, once the trial Moore et al inappropriately include as
a primary care trial is excluded, the results expressed as
risk ratios are surprisingly similar for both settings, both
in the subset of data presented by Cates [1], and the full
results of the review [10]. There is also little difference be-
tween the results using standard meta-analysis and the
treat-as-one-trial method, but as we noted above, al-
though use of the treat as one trial method increases the
risk of bias, bias will not always be seen.
Other points
Moore's method of grouping trials with similar control-
group event rates does appear to reduce the problem, as
would be predicted, but it cannot eradicate it. It is impor-
tant to note that this is a 'results based' categorisation that
is not based on a priori clinical criteria. Also, grouping by
control group event rate only reduces the bias for analysis
of risk differences, and not for relative effect measures. But
grouping by control group event rate leads to worse prob-
lems as the treatment effect is correlated with the control
group event rate [14].
Moore et al also say that an analysis based on pooling risk
differences assumes that the control group event rate is the
same in all trials. This statement is incorrect – what is as-
sumed (in a fixed effect analysis) is that the true treatment
effect expressed as a risk difference was the same in all tri-
als. There is no statistical assumption that the event rates
per arm are similar across trials. There may be other rea-
sons to worry about this issue, as discussed above.
Cates comments on the choice of effect measure for bina-
ry data. It is true that there is empirical evidence that rela-
tive effect measures are more likely to be homogenous
across trials this does not mean that absolute measures
should never be used. More seriously, it does not help us
unravel the choice between odds ratio and risk ratio,
where the empirical evidence shows no such dominance
of one measure [5,6].
Systematic reviews involve subjectivity, for example in de-
ciding which studies to analyse. It is essential that reviews
include the summary data from each study so that readers
can examine the implications of some of these judge-
ments [15]. The methods of analysis should also be spec-
ified, including the method to derive an estimated NNT.
For example, it would be misleading not to report the use
of the treat-as-one-trial method.
Conclusions
We agree with earlier comments from Moore and Mc-
Quay: "NNT is a tool. Like any tool, when used appropri-
ately it will be helpful and effective. What we have to do
is to ensure that in any given situation we know what the
rules are for using the tools correctly." [16]
Table 2: Results of meta-analyses of trials of high intensity nursing to reduce smoking using standard§ and 'treat-as-one-trial' methods, 
with relative risk as effect measure
Setting (no. of trials) Number quitting/total Pooled risk ratio (95% CI) NNT (95% CI)
Intervention Control
Hospital (7) 435/1367 318/1295
Meta-analysis 1.30 (1.16 to 1.47) 13.6 (8.7 to 25.5)¶¶
Treat-as-one-trial 1.30 (1.15 to 1.47) 13.8 (9.4 to 25.9)
Primary Care (3)* 111/2453 41/1006
Meta-analysis 1.01 (0.71 to 1.42) 2454 (58.4 to H84.6¶)¶¶
Treat-as-one-trial 1.11 (0.78 to 1.58) 222.5 (52.0 to H97.7¶)
Primary Care (2)** 87/2246 25/958
Meta-analysis 1.54 (0.97 to 2.44) 71.0 (26.6 to H1277¶)¶¶
Treat-as-one-trial 1.48 (0.96 to 2.30) 79.1(39.2 to H4369¶)
§ Mantel-Haenszel method (fixed effect) * as defined by Moore et al ** excluding reference [12]¶ NNT for harm [13]¶¶NNT calculated using the 
event rate among controls and the relative risk reduction [4]BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/3
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Given the choice between a method that always gives a
right answer and a method that sometimes or even usually
gives the right answer, it is common sense to use the one
that always gives the right answer. Adding numbers may
have some value for simple descriptive purposes, but the
treat-as-one-trial method should not be used for substan-
tive analysis.
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